Protagonist Therapeutics, Inc.
PTGX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $4,236,396 | $3,510,253 | $3,044,939 | $2,405,879 |
| - Cash | $113,713 | $168,543 | $139,653 | $97,249 |
| + Debt | $10,749 | $11,279 | $11,360 | $10,866 |
| Enterprise Value | $4,133,432 | $3,352,989 | $2,916,646 | $2,319,496 |
| Revenue | $4,712 | $5,546 | $28,321 | $170,638 |
| % Growth | -15% | -80.4% | -83.4% | – |
| Gross Profit | $4,712 | $5,546 | $28,321 | $170,638 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$38,978 | -$41,737 | -$19,071 | $127,316 |
| % Margin | -827.2% | -752.6% | -67.3% | 74.6% |
| Net Income | -$39,339 | -$34,771 | -$11,655 | $131,674 |
| % Margin | -834.9% | -627% | -41.2% | 77.2% |
| EPS Diluted | -0.62 | -0.55 | -0.19 | 1.98 |
| % Growth | -12.7% | -189.5% | -109.6% | – |
| Operating Cash Flow | -$1,937 | -$28,780 | $125,363 | -$29,178 |
| Capital Expenditures | -$88 | -$813 | -$545 | -$310 |
| Free Cash Flow | -$2,025 | -$29,593 | $124,818 | -$29,488 |